BIBLIOGRAPHY AND SUGGESTED READING

Acar S, Armstrong AE, Hirbe AC. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials. *Expert Opin Investig Drugs*. 2022;31(1):31–40.

Armstrong AE, Belzberg AJ, Crawford JR, et al. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas. *BMC Cancer*. 2023;23(1):553.

Botero V, Tomchik SM. Unraveling neuronal and metabolic alterations in neurofibromatosis type 1. *J Neurodev Disord.* 2024;16(1):49.

Cosmo E, Frizziero L, Miglionico G, et al. Choroidal abnormalities in pediatric NF1: a cohort natural history study. *Cancers*. 2022; 14(6):1423.

de Blank PMK, Gross AM, Akshintala S, et al. MEK inhibitors for neurofibromatosis type 1 manifestations: clinical evidence and consensus. *Neuro Oncol.* 2022;24(11):1845–1856.

Fisher MJ, Blakeley JO, Weiss BD, et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. *Neuro Oncol*. 2022;24(11):1827–1844.

Friedman JM. Neurofibromatosis 1. October 2, 1998 (Updated April 3, 2025). In: Adam MP, Feldman J, Mirzaa GM, et al., editors. *GeneReviews* (Internet). Seattle, Washington: University of Washington–Seattle; 1993–2025. https://www.ncbi.nlm.nih.gov/books/NBK1109/. Accessed May 2025.

Gaillard F. Optic pathway glioma. Radiopaedia website. https://radiopaedia.org/articles/optic-pathway-glioma. Updated April 3, 2025. Accessed May 2025.

Got Transition website. 2025. https://www.gottransition.org/. Accessed May 2025.

Gross AM, Dombi E, Wolters PL, et al. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. *Neuro Oncol.* 2023;25(10):1883–1894.

Gross AM, O'Sullivan Coyne G, Dombi E, et al. Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial. *Nat Med.* 2025;31(1):105–115.

Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas [published correction appears in: *N Engl J Med*. 2020;383(13):1290]. *N Engl J Med.* 2020;382(15):1430–1442.

Kerashvili N, Gutmann DH. The management of neurofibromatosis type 1 (NF1) in children and adolescents. *Expert Rev Neurother.* 2024;24(4):409–420.

Lalvani S, Brown RM. Neurofibromatosis type 1: optimizing management with a multidisciplinary approach. *J Multidiscip Healthc.* 2024;17:1803–1817.

Lee TJ, Chopra M, Kim RH, et al. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. *Orphanet J Rare Dis*. 2023;18(1):292.

Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. *Genet Med*. 2021;23(8):1506–1513.

Mallone F, Lucchino L, Giustini S, et al. An update on choroidal abnormalities and retinal microvascular changes in neurofibromatosis type 1. *Orphanet J Rare Dis*. 2022;17(1):223.

Mirdametinib (package insert). U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219379Orig1s000lbl.pdf. Revised February 2025. Accessed May 2025.

Moertel CL, Hirbe AC, Shuhaiber HH, et al. ReNeu: a pivotal, phase iib trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma [published correction appears in: *J Clin Oncol*. 2025;43(2):239]. *J Clin Oncol*. 2025;43(6):716–729.

Moodley M, Lopez KR. Neurofibromatosis type 1—an update. *Semin Pediatr Neurol*. 2024;52:101172.

Na B, Shah SR, Vasudevan HN. Past, present, and future therapeutic strategies for NF-1-associated tumors. *Curr Oncol Rep.* 2024;26:706–713.

National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Maryland, USA, July 13–15, 1987. *Neurofibromatosis*. 1988;1(3):172–178.

Radtke HB, Berger A, Skelton T, Goetsch Weisman A. Neurofibromatosis type 1 (NF1): addressing the transition from pediatric to adult care. *Pediatric Health Med Ther*. 2023;14:19–32.

Selumetinib (package insert). U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213756s004lbl.pdf. Revised January 2024. Accessed May 2025.

Solares I, Viñal D, Morales-Conejo M, et al. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review. *ESMO Open*. 2021;6(4):100223.

White PH, Cooley WC, et al. Supporting the health care transition from adolescence to adulthood in the medical home [published correction appears in: *Pediatrics.* 2019;143(2):e20183610]. *Pediatrics.* 2018;142(5):e20182587.